New Drugs in Development Overall, the pipeline for truly new drugs is not well filled. While a modest number of new agents are working their way through the development system, only a small portion of them is likely to help people who have failed earlier therapies.
Drugs aimed at new targets in the viral life cycle are few and far between.
This weakness in the new drug pipeline suggests that it will be very important over the next few years for people to do their absolute best to adhere to their existing regimens to get the longest possible use out of them. Without such careful adherence and wise treatment strategies, many people may run out of effective therapies well before new and better agents make it through the pipeline. Abbott Laboratories' second generation protease inhibitor, ABT-378, appears to be quite potent and well tolerated. ABT-378 and 100mg ritonavir again both taken twice a day. There were no differences between the two doses.